ArticleJournal of fluorescence2025
Development of Polymer-Based Fluorescent Nanocomposites for Synergistic Inhibition of Non-Small Cell Lung Cancer with Gefitinib.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prospects and Challenges of Chitosan-Based Drug Carriers for Anticancer Agents' Delivery Against Lung Cancer: A Review.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-small cell lung cancer (NSCLC) is a prevalent form of lung cancer, primarily including adenocarcinomas and squamous cell carcinomas. Advances in targeted therapies have significantly improved NSCLC treatment. In this study, we developed a multifunctional fluorescent imaging nanodrug delivery system using fructose as a natural cross-linker due to its biocompatibility and low toxicity. The incorporation of zinc phthalocyanine-perfluorinated resin (ZnPc-PFR) into chitosan-fructose (CH-Fru) resulted in a nanocomposite with superior fluorescent properties and high loading capacity for compound 1, creating CH-Fru@ZnPc-PFR@1. Furthermore, the combination of compound 1 and gefitinib formed the CH-Fru@ZnPc-PFR@1@Gefitinib composite system, which demonstrated a synergistic effect in inhibiting NSCLC cell proliferation. This study not only developed an effective nanodrug delivery system but also highlighted the potential therapeutic benefits of combining compound 1 with gefitinib for lung cancer treatment.
Indexed as
Identifiers
39992319What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.